Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplasty

Thromb Res. 1991 Jul 1;63(1):21-8. doi: 10.1016/0049-3848(91)90266-y.

Abstract

In a prospective randomized study heptest, thrombin-antithrombin complexes (TAT), D-dimer, and t-PA:ag were analysed pre- and postoperatively in 206 consecutive patients undergoing hip arthroplasty during thromboprophylaxis with either a LMW heparin (Enoxaparin) or Dextran 70. Deep vein thrombosis (DVT) developed in 6 of 102 (6%) Enoxaparin and in 21 of 104 (20%) Dextran patients diagnosed by bilateral phelobography. In the Enoxaparin group heptest showed a significant increase from the pre- to the postoperative level opposed to a significant decrease in the Dextran group. Postoperative levels of TAT, D-dimer, and t-PA:ag were significantly increased in both groups, however, TAT was significantly higher in patients in the Dextran group than in the Enoxaparin patients. D-dimer was significantly higher in Dextran patients with DVT postoperatively compared with patients without DVT. No differences concerning TAT or t-PA:ag were observed between patients with and without DVT in any of the groups.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Coagulation / drug effects
  • Dextrans / pharmacology*
  • Female
  • Fibrinolysis / drug effects
  • Heparin, Low-Molecular-Weight / pharmacology*
  • Hip Prosthesis / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Thrombolytic Therapy
  • Thrombophlebitis / blood
  • Thrombophlebitis / prevention & control*

Substances

  • Dextrans
  • Heparin, Low-Molecular-Weight